# KalVista Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/KalVista Pharmaceuticals, Inc.). ## Overview KalVista Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing oral therapies for hereditary angioedema (HAE). Its lead product, EKTERLY (sebetralstat), received FDA approval in July 2025 and the company has begun U.S. commercial operations while also pursuing ex-U.S. partnering opportunities. ## Products & services • EKTERLY (sebetralstat) oral therapy for acute HAE attacks • Commercialization of EKTERLY in the United States • License, supply and distribution partnerships for ex-U.S. markets • Clinical development of additional product candidates • Regulatory submissions and manufacturing supply for partners - **Commercial product sales** (85%) — Sales of EKTERLY in the U.S. following FDA approval. - **License and collaboration revenue** (15%) — Upfront, milestone, and royalty income from regional licensing deals. - **Clinical development programs** (0%) — Research and development work on sebetralstat and other pipeline candidates. - EKTERLY (sebetralstat) for acute hereditary angioedema attacks - U.S. commercial launch and promotion of EKTERLY - Out-licensing of sebetralstat in Japan and Canada - Clinical development of sebetralstat and other pipeline assets - Manufacturing and supply of licensed product to partners ## Customers The core customer base is allergists and immunologists, who account for most HAE prescribing and claims in the U.S. EKTERLY is ultimately bought through the specialty pharmacy and payer channel, with access and reimbursement decisions shaping uptake. Outside the U.S., KalVista also serves regional pharmaceutical partners that commercialize or seek approval for sebetralstat in their own markets. - **U.S. HAE prescribers** (primary) — Allergists and immunologists who prescribe EKTERLY for acute HAE attacks and drive adoption. - **Commercially insured HAE patients** (primary) — Patients who receive EKTERLY through specialty pharmacy channels and benefit programs. - **Payers and pharmacy benefit managers** (primary) — Organizations that determine formulary access, reimbursement, and patient out-of-pocket costs. - **Specialty pharmacies** (secondary) — Channel partners that dispense product, manage inventory, and support distribution. - **International license partners** (secondary) — Companies such as Kaken and Pendopharm that commercialize or seek approval in local markets. - Allergists and immunologists prescribing HAE treatment - Commercially insured HAE patients using specialty pharmacies - Payers and pharmacy benefit managers influencing access - Specialty pharmacies dispensing EKTERLY and managing distribution - Regional partners such as Kaken and Pendopharm ## Geography KalVista’s commercial focus is currently the United States, where EKTERLY launched after FDA approval in July 2025. The company is also building an international footprint through licensing agreements in Japan and Canada, while retaining manufacturing and regulatory responsibilities for those markets. Geography matters because near-term revenue is concentrated in the U.S., but future growth depends on partner-led expansion abroad. - **United States** (100%) — All disclosed product revenue in the period came from the U.S. launch of EKTERLY. - United States is the first commercial market for EKTERLY - Japan is licensed to Kaken for local commercialization - Canada is licensed to Pendopharm for regulatory and commercial rights - Company retains supply and regulatory responsibilities for Japan - International expansion is expected to be partner-led rather than direct ## Strategy KalVista’s strategy is to convert EKTERLY from a development asset into a commercial product in the U.S. while using partnerships to extend reach in non-U.S. markets. The company is also investing in market access, a specialty sales force, and manufacturing/supply capabilities to support launch execution and future label expansion. - **U.S. commercialization of EKTERLY** (short-term) — Near-term value creation depends on converting FDA approval into prescriptions and payer coverage. - **International partnering** (medium-term) — Licensing reduces the cost of global expansion while preserving upside through milestones and royalties. - **Supply and regulatory execution** (short-term) — Commercial success depends on reliable manufacturing, regulatory maintenance, and product availability. - Drive U.S. adoption of EKTERLY after FDA approval - Build market access and specialty sales capabilities - Use licensing deals to expand internationally with lower capital intensity - Retain manufacturing and regulatory control where strategically important - Continue pipeline development to reduce dependence on one product ## Risks KalVista is still highly dependent on EKTERLY, so commercial uptake, payer access, and physician adoption will largely determine near-term performance. The company also faces typical biotech risks around funding needs, manufacturing reliability, regulatory execution, and competition from other HAE therapies. Because it is early in commercialization, execution risk is elevated and revenue visibility remains limited. - **Dependence on EKTERLY commercialization** [high] — The company’s value and revenue base are concentrated in a single approved product. - **Insufficient market acceptance** [high] — Prescriber adoption and payer coverage determine whether the launch converts into durable sales. - **Funding and dilution risk** [high] — The company has a history of losses and may need more capital to support commercialization and R&D. - **Manufacturing and supply risk** [medium] — Product availability depends on third-party manufacturing and distribution execution. - **Competitive pressure in HAE** [medium] — Other pharmaceutical companies market or develop therapies for the same indication. - Heavy dependence on one product, EKTERLY - Commercial launch risk if physicians or payers adopt slowly - Need for additional capital if launch or pipeline spending rises - Manufacturing and supply chain disruptions could limit sales - Competition from established and emerging HAE therapies ## Accounting Revenue recognition is now important because EKTERLY sales are subject to co-pay assistance, prompt-pay discounts, distribution fees, and product return reserves that reduce reported net product revenue. The company also has milestone and royalty arrangements under licensing deals, which require judgment on timing and measurement. As a pre-profit commercial-stage biotech, operating leases, clinical accruals, and fair-value estimates for contingent obligations can materially affect reported results. - **Revenue deductions and reserves** — Can materially change reported EKTERLY revenue in early launch periods - **Milestone and royalty accounting** — Affects collaboration revenue and deferred revenue balances - **Clinical and commercial accruals** — Can cause quarter-to-quarter expense volatility - **Lease accounting** — Creates right-of-use assets and lease liabilities - Net product revenue is reduced by rebates, discounts, and return reserves - Launch-period revenue may be volatile as channel inventory builds and normalizes - Milestone and royalty accounting affects collaboration revenue timing - Clinical trial and manufacturing accruals depend on management estimates - Operating leases and contingent obligations affect liabilities and expense recognition --- *Last updated: 2026-04-28T20:19:58.717761+00:00*